Abstract. The aim of the present study was to compare the effectiveness of different modes of mechanical ventilation in combination with secretolytic therapy with ambroxol in premature infants with respiratory distress syndrome.
Introduction
Infant respiratory distress syndrome (IRDS) is a leading cause of mortality in infants, affecting ~1% of newborn infants (1) . Preterm babies with this condition are unable to adequately produce surfactant in the lungs due to the structural immaturity of their lungs. Surfactant is produced after ~30-32 weeks gestation, and thus preterm babies born prior to 30 weeks gestation are likely to develop IRDS (2) . The prime reason for IRDS is developmental insufficiency, and in many cases it is caused by a genetic problem with lung development.
The management of IRDS involves the use of artificial respiratory support along with surfactant administration (3) . Previous findings have confirmed the efficacy of these treatments in reducing mortality as well as morbidity caused by IRDS (4) (5) (6) . Ambroxol is a secretolytic agent that was used in the present study. It is a mucoactive drug that stimulates the synthesis as well as the release of surfactants by type Ⅱ pneumocytes (7) . In physiological terms, surfactants reduce the adhesion of mucus to the bronchial wall, and improve its transport and provide protection against infections and irritating agents. On the other hand, artificial respiratory support in the form of mechanical ventilation aims to treat the hypoxaemia and hypercarbia associated with respiratory distress syndrome while minimising ventilator-associated lung trauma and oxygen toxicity (7) .
Conventional mechanical ventilation (CMV) involved the delivery of a fixed number of breaths per minute via positive pressure ventilation, regardless of the baby's inspiratory effort (2, 8) . It is associated with various side effects, including injury to the airways and lung parenchyma due to its invasive nature (9) . These side effects led to the invention of modern mechanical ventilation methods including high frequency oscillatory ventilation (HFOV), which can be set to trigger or to coincide with the baby's inspiratory efforts (10, 11 (12, 13) . However, there is a paucity of information with regard to comparative analyses of these two modes when combined with surfactant therapy. Therefore, in the present study we compared the effects of CMV and HFOV when both are combined with secretolytic therapy (ambroxol) on respiratory distress syndrome in premature infants. Patients in the HFOV group were treated with a Fabian neonatal high-frequency ventilator, with the initial FiO 2 at 0.5-0.8 and frequency at 9-12 Hz. The mean airway pressure (MAP) was adjusted to the arterial CO 2 tension level, although 11-13 cm H 2 O was initially used prior to an increase every 10-15 min. FiO 2 was adjusted via SpO 2 monitoring, until oxygenation was increased. The target blood gas values were maintained as follows: PaO 2 , 50-70 mmHg and PaCO 2 , 35-50 mmHg. After the condition improved, the parameters for FiO 2 and MAP were reduced.
Materials and methods

Study
Secretolytic therapy. The two groups were administered secretolytic therapy in the form of bovine pulmonary surfactant (PS) (Beijing Double-Crane Modern Pharmaceutical Technology Co., Ltd., Beijing, China). The first dose consisted of 70 mg/kg, and was administered according to the manufacturer's instructions. Administration was repeated 1-3 times, dosing intervals were every 6-12 h and the majority of patients were administered therapy 3 times. The method of administration was via an aseptic nasal feeding tube. Endotracheal intubation was extended to the edge of the intubation with the assistance of endotracheal instillation. The total duration of the therapy was 7 days.
Statistical analysis. SPSS 19 software (IBM Corp., Armonk, NY, USA) was used to perform statistical analysis. The data were presented as the means ± SD. The Student's t-test was used for comparisons between the groups. Count data were expressed as percentages. The χ 2 test was used to test significant association (if any) between the variables. P<0.05 indicated a statistically significant difference.
Results
A total of 73 cases were randomly divided into two groups on the basis of the type of mechanical ventilation used. Thirty-three infants with average ages of 32.35±1.95 weeks were given CMV. The remaining 40 infants, average ages of 33.13±2.04 weeks, were treated with HFOV. The two groups were treated with secretolytic therapy with ambroxol. The differences in the general clinical indices (Table I ) of the two groups were not statistically significant, thus confirming the uniformity of the present study. Additionally, Apgar scores ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- and prenatal hormone usage (%) did not show any statistically significant difference. On the other hand, a statistically significant improvement (Table II) was observed in the PaO 2 of the HFOV group as compared to that of the CMV group after 1, 2 and 12 h of treatment. In addition, FiO 2 was significantly decreased (Table III) in the HFOV and CMV groups. Combined treatment led to a significant improvement in the PaO 2 /FiO 2 (PF) ratio (Table II) of the lungs in the HFOV group as compared to the CMV group. Furthermore, no significant differences were recorded in PaCO 2 or pH values (Table II) between the two groups. In our evaluation of the oxygenation index (OI) in IVRD infants, a significant decrease (Table Ⅲ) in the HFOV group in comparison with that of the CMV group was identified. Moreover, the arterial/alveolar oxygen tension ratio (a/APO 2 ) ratios demonstrated a statistically significant increase (Table Ⅲ) in the HFOV group as compared to the CMV group after each time interval of treatment. However, MAP values did not differ significantly between the two groups. As shown in Table Ⅳ , there were no significant differences between the groups with regard to complications such as motality, pneumothorax, bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL).
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Discussion
The present study compared the effectiveness of combined therapy comprising HFOV and secretolytic therapy (using ambroxol) to that comprising CMV and secretolytic therapy (using ambroxol) in premature infants with respiratory distress syndrome. The results clearly show the efficacy of HFOV over CMV in 73 premature infants. In the present study, we tested preterm infants in the two groups using the arterial blood gas (ABG) test. The ABG test is one of the most widely used tests in cases of respiratory distress syndrome, as it provides essential information concerning gas exchange across the alveolar-capillary membrane (14) . It measures PaO 2 , PaCO 2 , and the pH of an arterial blood sample.
The PaO 2 of infants in the HFOV group improved significantly as compared to that of the CMV group. Measuring PaO 2 revealed the partial pressure of oxygen in the blood, which is significant, as it is directly associated with ventilation and oxygenation. In respiratory distress syndrome, oxygen tension is decreased by ≤50 mm. In the present study, the treatment with CMV and ambroxol improved partial oxygen tension levels. The positive pressure delivered by CMV likely contributed to the observed increase in PaO 2 . Furthermore, the improvement in PaO 2 was much greater in the HFOV group, and it increased to >65 mm. The reason for this improvement is that HFOV delivers extremely rapid rates (~600-800 breaths per min) of very small tidal volumes. Moreover, HFOV coincides with the patient's inspiratory efforts, which contributes to an increase in arterial oxygen tension, as has been previously noted (15) .
This evaluation of respiratory function revealed that FiO 2 levels were significantly decreased in the two groups following treatment with combination therapy. However, greater moderation was observed in the HFOV group. FiO 2 values provide us with an estimate of oxygen involvement in gas exchange in alveoli. FiO 2 values are crucial, as they directly affect the Carrico index (the PaO 2 /FiO 2 ratio), which is the ratio of pulmonary arterial oxygen tension to the fraction of inspired oxygen (16) . In other words, the Carrico index is useful in determining the ability of the lungs to transfer oxygen to the blood. Usually, the Carrico index is low in IRDS patients. In the present study, we observed a significant decrease in FiO 2 values in the two groups of premature infants with IRDS and a significant improvement in the Carrico index of the two groups. However, the improvement was much greater in the HFOV group, due to a greater reduction in FiO 2 caused by higher breathing rates, as compared to the CMV group.
The OI is another crucial parameter that provides us with information concerning FiO 2 as well as O 2 utilization. The lower the OI is, the better the physiological function of the lungs. The OI is directly proportional to FiO 2 values and inversely proportional to PaO 2 values. Thus, the decreased FiO 2 values and elevated PaO 2 following the combination treatment in the HFOV group resulted in a lower OI. Therefore, the marked decrease in the OI confirmed the effectiveness of HFOV over CMV. Addtionally, estimation of these indices allowed us to evaluate the a/APO 2 ratio, which was also significantly improved in the preterm babies of the HFOV group.
It can be concluded from the present study that HFOV is a more viable option than CMV when combined with secretolytic therapy using ambroxol to treat preterm babies with respiratory distress syndrome. This method may become the gold standard for preterm infants with respiratory distress syndrome in the future.
